NeuroQuest is a drug development company seeking new approaches to modulation of nerve transmission and promising clinical applications particularly for neuropathic pain. The company focuses on a first-in-class small molecule drug discovery platform which is based on bioactives discovered in plant extracts showing efficacy for neuropathic pain. This is an unusually novel and promising opportunity which focuses on the development of a novel class of analgesics.
In addition to its core focus on nerve modulation, NeuroQuest is also isolates and elucidates medicinal agents from plants, and then designs new synthetic drug compounds based on those plant-derived agents. The company provides reliable contract isolation, synthesis and manufacturing of native compounds or API’s and advanced intermediates to the biopharma industry.
NeuroQuest has a joint venture agreement with Concept 2 Clinic for the commercial development of several products for nerve pain in various global markets.
NeuroQuest is housed within the Halifax National Research Council laboratories, providing state-of-the-art analytical equipment, screening assays and a wide range of technical and scientific expertise. NeuroQuest is a wholly-owned subsidiary of Neurodyn Life Sciences. Related to NeuroQuest’s work, a sister company CNS|CRO provides highly predictive neurological animal models to the industry.
There is very high interest in the biopharmaceutical sector for novel classes of chemistry that exploit new mechanisms of action for nerve modulation, especially for the treatment of neuropathic pain. NeuroQuest will seek high-value applications for pain relief and other medical conditions that respond to the modulation of nerve function. The company plans to take its first lead candidate drug into the clinic within one year with an initial product approval timeframe as early as two years.
This research is backed by strong, first-in-field patent protection in all major jurisdictions. The company will seek several out-license opportunities for its platform technology, each for a specific disease indication. Alternatively, the potential exists for a full divestiture to a large pharma player.